...holding company, and later housed in the IFM Tre Inc....

...I-O Portfolio” ). After spinning out of IFM Therapeutics Inc., IFM Therapeutics LLC formed the IFM Tre Inc....

...Novartis has engaged in a variety of deal styles. It has acquired Endocyte Inc. and IFM Tre Inc....

...to join in. Within one year of launching with a $31 million series A round, IFM Tre Inc....

...target in liver disorders, has compelling potential in neurodegenerative diseases. Last week, Novartis AG acquired IFM Tre Inc....
...NASDAQ:FLDM), South San Francisco, Calif. Foghorn Therapeutics Inc., Cambridge, Mass. Fulcrum Therapeutics Inc., Cambridge, Mass. IFM Tre Inc....

...IPO from companies working on non-alcoholic steatohepatitis (NASH) programs. On April 1, Novartis AG acquired IFM Tre Inc....

...also eligible for up to $1.3 billion in milestones. IFM Therapeutics LLC (Boston, Mass.) launched IFM Tre Inc....

...all have programs in NASH. Inflazome is developing an NLRP3 inhibitor for Parkinson’s disease. The IFM Tre Inc....

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...protein 173 IFM Therapeutics LLC, Boston, Mass. Business: Autoimmune, Inflammation, Neurology Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...

...antagonists of NLRP3 to treat inflammatory diseases. Those programs were later housed in initial subsidiary IFM Tre Inc....
...family pyrin domain containing 3; STING (TMEM173) - Transmembrane protein 173 Paul Bonanos IFM Therapeutics Inc. IFM Therapeutics LLC IFM Tre Inc. cGAMP...